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It is largely unknown why certain infected hosts shed Herpes Simplex Virus-2 (HSV-2)
more frequently and have more severe disease manifestations than others. One idea is
that different density or functional capacity of tissue resident effector memory CD8+T-cells
between infected persons may explain phenotypic variability. To generate hypotheses for
contrasting shedding patterns in different infected hosts, a spatial mathematical model was
employed to evaluate the effects of variability in tissue resident effector memory CD8+
T-cell response, and HSV-2 replication and spread, on viral shedding rate. Model simula-
tions suggest that high levels of CD8+ T-cells in the mucosa do not necessarily indicate
a protective phenotype but rather an effective response to recent shedding. Moreover,
higher CD8+ T-cell expansion rate and lower viral replication rate, which correlate with
better short-term control, may have only a minor impact on long-term shedding rates.
Breakthrough shedding occurs under all sets of model parameter assumptions, because
CD8+T-cell levels only surpass a protective threshold in a minority of genital tract mucosal
micro-regions. If CD8+ T-cell levels are artificially increased using an immunotherapeutic
approach, better control of shedding is predicted to occur for at least a year. These results
highlight the complex co-dependent relationship between HSV-2 and tissue resident CD8+
lymphocytes during the course of natural infection.
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INTRODUCTION
A question at the core of infectious diseases research is why differ-
ent patients exhibit heterogeneous disease severity when exposed
to equivalent pathogens. This question is especially relevant for
Herpes Simplex Virus-2 (HSV-2) infection, which is character-
ized by variable genital tract shedding, as well as recurrent gen-
ital lesions in many, but not all patients. Approximately 20% of
patients are completely asymptomatic despite shedding virus (1,
2); on the other extreme, some patients recur more than 10 times
per year, and others suffer from recurrent meningitis (3). Several
informative cross-sectional studies have identified specific innate
immune deficits that correlate with severe disease outcomes during
HSV-1 infection (4, 5), which causes both oral and genital ulcers,
and has close genetic homology to HSV-2. Other studies demon-
strated that at a broad level, deficits in T-cell functionality correlate
with higher recurrence rates (6, 7). Yet, these studies do not allow
a full mechanistic explanation for disease variability, and ignore
important non-linear dynamic features of the immune response as
well as viral replication. It is not understood, even at a basic level,
why some patient shed more than others, and why many patients
suffer while others remain completely asymptomatic.
There is currently an intense focus on the role of tissue resi-
dent CD8+ effector memory T-cells in rapidly containing HSV-2
infection (8–11). In humans, these cells are present in high local
abundance at the site of viral replication during genital ulcers
(12, 13). Importantly, tissue resident CD8+ lymphocytes persist
for months at the site of HSV-2 release from neurons into the
genital tract and at the single cell level, retain an activated effec-
tor memory phenotype, even in the absence of viral reactivation
(14, 15). In animal models, tissue resident CD8+ T-cells can be
“pulled” from blood to tissue using local inflammatory mediators,
a promising observation for vaccine developers (16). Upon arrival
to the mucosa, these cells actively patrol between epithelial cells
(17), and rapidly contain HSV replication with re-challenge of
virus (9, 18).
It is therefore tempting to invoke variability in function and
number of CD8+ T-cells as a key determinant of inter-subject
shedding variability (19). Dense imprints of HSV-2 specific CD8+
lymphocytes in genital tissues may represent a protective pheno-
type against subsequent high levels of genital shedding. Yet, the
temporospatial dynamics of tissue resident cells toward HSV-2 are
complex because HSV-2 reactivation occurs approximately every
week, implying more leaky control of HSV over brief time scales
(20): a high abundance of tissue resident HSV-2 specific CD8+ T-
cells may simply reflect recent local containment of virally infected
cells rather than prospective immunologic protection. The relative
stability of shedding rates in humans over decades of infection
supports this idea (21).
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Studying this problem in humans is complicated by the fact that
immunologic sampling of the genital tract is limited to millime-
ter tissue sections, and CD8+ T-cells expand and contract within
hundreds of genital tract microenvironments, resulting in spatially
heterogeneous potential for viral growth (22). While some geni-
tal tract areas may be protected, other potential regions of viral
reactivation lack protective T-cell immunosurveillance. This spa-
tial variability is an extremely important, but typically overlooked,
feature of the mucosal immune response. While HSV-2 severity
can be compared between study subjects using total genital tract
shedding rate and lesion rate, as outcome measures (23), the over-
all intensity and spatial variability of the immune response is not
easily measured at the whole tissue level.
In this study I use a published mathematical model to simulate
heterogeneous shedding rate in different infected persons while
also developing predictions regarding the relationship between
viral shedding and CD8+ T-cell spatial density and functionality
over long time frames. The model describes competition between
HSV-2 replication in mucosal epithelial cells, and CD8+ T-cell
elimination of these infected cells (19, 23, 24). Because HSV-2
lesions consists of multiple ulcers, viral replication is assumed
to be widespread across the genital tract (25), and CD8+ T-cell
expansion is assumed to localize to micro-regions of viral replica-
tion (12, 13). Equations are structured to allow multiple, spatially
discrete, concurrent foci of replication and immunological con-
tainment. Model parameters characterize rates of viral replication
and spread, death rate of infected cells, and kinetics of CD8+
T-cell expansion, decay, and cell lysis. Several spatial phenom-
ena are captured by the model including widely dispersed viral
release from neurons into multiple regions of the genital tract,
seeding of adjacent regions of genital skin by virus from a single
ulcer, and measurement of immunologic distance between newly
seeded ulcers (22). The model’s key emergent property is shedding
rate, which is influenced to varying degrees by all of these biologic
processes.
The model previously reproduced detailed kinetic features
from merged data consisting of 14,685 genital swabs and 1,020
shedding episodes from 531 study participants (22). It therefore
provides a general biologic framework to explain general shed-
ding episode patterns that are evident in most infected persons.
However, because episode initiation is difficult to predict, episode
severity varies dramatically over 30 to 60-day sampling periods
in clinical studies, and viral load trajectories are highly erratic
and non-linear, the model is not easily fit to data from individual
patients, and has not been used as a tool to explain inter-subject
shedding variability.
Here I perform global sensitivity analysis to isolate model para-
meters that have the greatest impact on HSV-2 genital shedding
rate. In simulations, high levels of overall CD8+ T-cell density do
not correlate with better control of virus. In fact, high shedding
appears to drive the frequency of mucosal T-cell turnover. Regard-
less of shedding rate, large sections of the genital tract have low
enough CD8+ T-cell levels to remain susceptible to more severe
episodes, highlighting that HSV-2 capitalizes on spatial hetero-
geneity of local immunity to allow occasional high-titer, prolonged
shedding episodes. As in clinical studies, an important simulated
determinant of long-term shedding rate is episode rate, which in
turn is strongly influenced by rate of release of HSV-2 from neu-
rons into the genital tract. Surprisingly, parameter values, such as
increased mucosal CD8+ T-cell expansion rate or decreased viral
replication rate in keratinocytes, that imply more robust short-
term virologic control in genital mucosa, have little impact on
long-term shedding rate. These results suggest that while tissue
resident CD8+ T-cells are critical in HSV-2 containment during
the natural history of infection, high local tissue density does not
necessarily imply better control. Yet, if natural dynamics of infec-
tion are perturbed with an immunotherapy leading to an increase
in overall density of tissue resident CD8+ T-cells, then shedding
rate is predicted to decrease for at least a year.
MATERIALS AND METHODS
ANALYSIS OF SHEDDING DATA
The data informing model design was from studies in which HSV-
2 seropositive participants performed swabs of the genital tract
every 24 h, whether lesions were present or not, for a minimum
of 30 days. Swabs were processed for quantitative HSV DNA poly-
merase chain reaction (PCR) using PCR. Detection of HSV DNA
was performed using a well-validated collection and detection
method (26–28) and was expressed as copies per milliliters of
medium.
To provide a detailed quantitative summary of episodic shed-
ding, eight summary measures were used: (1) quantitative shed-
ding rate was evaluated on a per swab basis with a frequency
histogram that stratified viral load into bins according to increases
in log-value (102–103, 103–104. . . HSV DNA copies); seven mea-
sures applied to specific episode characteristics (Figure 1): four
frequency histograms were used to describe heterogeneity in (2)
peak, (3) first, and (4) last positive HSV DNA copy number within
an episode (bins were again separated by log-value of HSV DNA),
as well as (5) episode duration (bins separated by number of
days); median episode measures included slopes from (6) initi-
ation to episode peak and (7) peak to termination, as well as (8)
episode frequency. Initiation to peak slopes were calculated with
the assumption that episodes initiated 12 h before the first pos-
itive swab respectively, and peak to termination slopes with the
assumption that episodes ended 12 h after the last positive swab
respectively (22, 29).
MODEL SIMULATIONS
The model in this paper has been described in detail elsewhere
(22) and is diagramed in Figure 2. The model consists of 300
possible micro-regions of infection, linked by (1) the ability of
neurons to randomly release virus into any of the 300 regions, (2)
the ability of virus from a herpetic ulcer in one region to seed a
new herpetic ulcer in an adjacent region, and (3) the ability of
CD8+ T-cells from one region to influence viral containment in
an adjacent infected region. The 300 micro-regions are arrayed in
a two-dimensional matrix of hexagons such that cell-free particles
from a region can only infect a maximum of six other regions
(Figure 2A), thus limiting rate of HSV-2 spread from region to
region within the genital tract. For edge regions, there are only
four contiguous regions at risk. These limitations on creation of
new ulcer spread are imposed to account for the clustered nature
of genital ulcers in infected people.
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The HSV-2 replication cycle and immunologic response to
HSV-2 infected cells within a single genital tract microenvi-
ronment can be referenced to each of the model’s parameters
(Figures 2B,C). During HSV-2 reactivation, virions are released
from neuronal endings at the dermal-epidermal junction at a
FIGURE 1 | Shedding episode classification scheme: from Schiffer
et al., J Antimicrob Chemother. 2011;66(11):2593–600. (29).
certain rate (φ). Released HSV-2 survives in the genital tract
for a defined duration (1/c) during which time it can transfer
from neurons and infect local epithelial cells. Viral infectivity
[1/(βi× S)] is roughly defined as the number of viruses that are
needed to infect one epithelial cell per day assuming the con-
stant presence of viruses and a full complement of susceptible
cells. For all of the models in this manuscript, there is some
degree of target cell limitation within each micro-region, by virtue
of susceptible cells decreasing relative to total number of cells
with time.
I assumed that if an epithelial cell becomes infected, then it will
die via direct lysis if it survives long enough to become packed
with viruses (lifespan= 1/a), or via CD8+ lymphocyte (E) medi-
ated killing [lifespan= 1/(f× E)]. Lymphocyte killing efficiency
(f ) is defined as the number of infected cells cleared by one CD8+
lymphocyte cell per day in vivo. If an epithelial cell evades CD8+
lymphocyte mediated killing for the entire duration of cellular
infection, it will produce a total of p/a viruses: p is the rate of
viruses produced by an infected cell per day. Re-growth of sus-
ceptible keratinocytes occurs according to a growth rate, λ or
d × (S0− S) with growth limited by S0, the carrying capacity of
the system.
The formation of a genital lesion is accompanied by rapid accu-
mulation of localized CD8+ lymphocytes at the dermal-epidermal
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FIGURE 2 | Spatial mathematical model. (A) Seven of 300 micro-regions are shown to indicate that cell-free virus from a single region can infect adjacent
regions. (B) Model equations. (C) Model diagram indicating viral production, spread, and local CD8+T-cell response: from Schiffer et al., eLife 2013;2:e00288.
(22).
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junction at a peak rate (θ), followed by slow decay of these cells
over a period of months after lesion healing (lifespan= 1/δ). The
CD8+ replication rate in our model is saturated at θ, and θ/2
occurs when infected cells are equal in number to parameter r,
which represents how many epithelial cells need to be infected
prior to half-maximal CD8+ expansion. Therefore, parameter r
defines how rapidly immune cells recognize and respond to viral
antigens on the surface of infected cells. Local replication of CD8+
T-cells rather than trafficking from other sites is the most math-
ematically likely means of viral control (19, 24). For each fitting
simulation, there is included a minimum value of E within each
region to reflect low numbers of CD8+ T-cells observed in nearly
all biopsy studies to date.
Cell-associated HSV-2 is differentiated from cell-free HSV in
the model and it is assumed that cell-associated particles (V i) can
passage from cell-to-cell within one microenvironment as soon
as they form within a cell (30). This process allows viral ulcers
to spread in a radial fashion. Cell-associated particles (V i) con-
vert to cell-free virus (V e) after infected cells rupture (Figure 2C).
Because swabs probably do not remove most cell-associated par-
ticles and infected cells (otherwise swabbing would mitigate shed-
ding), V e is fit to the data. Cell-free particles can initiate formation
of new plaques within adjacent regions by local seeding in our
model, and are assigned an infectivity parameter (βe). Parame-
ter (ε) is included to account for delay in viral production within
secondary plaques after seeding.
The 300 regions are linked immunologically according to para-
meter ρ. When an ulcer is initiated in a region (infection of a single
epidermal cell), the CD8+ T-cell density is assumed to include a
certain proportion of CD8+T-cell density in surrounding regions:
we include this parameter to acknowledge that there are in fact no
discrete immunologic borders between regions as assumed in the
model. If ρ= 0, then CD8+ T-cell density in a region is inde-
pendent of surrounding regions. This implies that all immunity
is localized only to an area with viral replication. If ρ= 1, CD8+
T-cell density in a region is assumed to equal the average from
surrounding regions.
The reproductive number [R= (p× βi× S0)/(a+ fE)× c] is
continually updated during each simulation. The reproductive
number is the average number of cells that an infected cell would
infect assuming the presence of CD8+ T-cells. For the spatial
model, which divides the genital tract into 300 separate regions
that are susceptible to viral replication, I calculated R separately
within each region.
A feature of the model is sensitivity to CD8+ T-cell density at
episode onset, which has an important effect on amount of virus
produced per episode (19). To avoid creating a bias on model out-
comes due to initial CD8+ T-cell values, the model was simulated
with its particular parameter set for 365 days, and then the CD8+
T-cell values in each region were used as the starting values for the
recorded simulation. Each simulation started with zero infected
cells and viruses.
SENSITIVITY ANALYSIS
Two hundred unique parameter sets were generated by randomly
selecting each parameter value using Latin hypercube sampling
from probability distribution functions of each parameter (pdfs).
The pdfs were constructed by normalizing around best-fit val-
ues from model fitting in previous simulations of the model (22,
24). The 10 parameters are included in Table 1. Viral replica-
tion rate was converted to a log-value prior to normalization
to expand variability of this parameter. Simulations were per-
formed over 10 years and parameter values were correlated with
several outcomes including shedding rate, episode rate, and area
under the curve which was calculated by measuring the sum of
[(V e,t+V e,t+ 0.001)/2]× 0.001 over the course of the simulation.
To allow for more parameter variability, I expanded the stan-
dard deviation of each parameter twofold and conducted a sec-
ond otherwise equivalent set of global sensitivity analyses. These
results did not alter the trends observed with a narrower standard
deviation and as such are not included in the manuscript.
ASSESSING MATHEMATICAL MODEL FIT TO EMPIRICAL DATA
All simulations were performed using C++. Model simulations
with each of the unique parameter sets were assessed for their
fit to a cumulative measure of the eight summary measures (42
data bins). The model was solved stochastically due to the ran-
dom nature of shedding episode initiation and clearance, and to
account for frequent presence of low numbers of infected cells: at
each time step, integer values for equation terms were drawn ran-
domly from binomial distributions. To assess degree of fit between
model numerical output and empirical data required prolonged
simulations of 10-year duration to minimize fluctuations in out-
put due to stochastic effect. Model variables were updated at a
narrow time interval (0.001 days). However, for assessing fit to
data, we assembled the modeled data exactly as it was gathered in
the clinical protocols by sampling every 24 h.
Each unique parameter set was assigned a least squares fit score
by the following methods. First, I assigned each of the summary
measures [(1) episode rate, (2) episode duration, (3) median ini-
tiation to peak slope, (4) median peak to termination slope, (5)
first positive copy number of episodes, (6) last positive copy num-
ber of episodes, (7) peak positive copy number of episodes, and
(8) per swab quantitative shedding] a weighting factor to ensure
that each summary measure carried an equivalent weight. Using
the empirical data, the mean value of bins within each of the five
histograms [(1) episode duration, (2) first positive copy number
of episodes, (3) last positive copy number of episodes, (4) peak
positive copy number of episodes, and (5) quantitative shedding]
was calculated; the inverse square of this value was then used to
generate an initial weighting factor, which was then divided by
the number of bins within the histogram such that each bin was
assigned a bin weighting factor. The three median measures [(1)
episode rate, (2) median initiation to peak slope, and (3) median
peak to termination slope] only contained one bin such that the
initial weighting factors were equal to the bin weighting factors.
For each bin, the difference between the empirical data and
model output was squared and multiplied by the bin weighting
factor for the bin, to arrive at a bin score. Each simulation with a
unique parameter set was given a least squares fit score equal to the
sum of these 42 bin scores with a lower score representing better
model fit. Unique parameter set simulations with the lowest least
squares fit score tended to capture all critical dynamical features of
HSV-2 shedding.
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Table 1 | Parameter ranges used for sensitivity analysis.
Parameter Units Symbol Mean SD
Cell-associated HSV infectivity DNA copy days/cell (viruses needed per day to infect one adjacent cell) βi 6.3e−8 7.5e−9
Cell-free HSV infectivity DNA copy days/cell (viruses per day to initiate one ulcer) βe 2.2e−11 2.5e−12
Epidermal HSV replication rate log 10 HSV DNA copies/cell/day p 5.05 0.05
Neuronal release rate HSV DNA copies/day/genital tract φ 68 11
Free-viral decay rate Days-1 (half-life, hours) c 8.4 0.7
Maximal CD8+T-cell expansion rate Days-1 Θ 2.6 0.35
CD8+T-cell decay rate Days-1 (half-life, days) δ 1.4e−3 1.4e−4
CD8+T-cell local recognition Infected cells at which Θ is half-maximal r 39 4
CD8+ regional co-dependence 0=no co-dependence, 1= full co-dependence ρ 0.72 0.07
Viral production lag Days ε 0.8 0.15
Normal distributions were assumed.
RESULTS
SHEDDING RATE IS THE MOST IMPORTANT CLINICAL OUTCOME
In 200 model simulations, each with a unique randomly selected
parameter sets, shedding was episodic and episodes were hetero-
geneous according to duration and viral production (Figure 3A).
Shedding rates were highly variable, ranging from 0 to 44% akin
to rates described in clinical studies (26–28). Shedding rate cor-
related precisely with viral area under the curve for each simu-
lation (Figure 3B), confirming a finding from empirical datasets
that shedding rate strongly predicts a composite measure of fre-
quency and quantity of shedding. Shedding rate is therefore the
most convenient and reproducible measure of disease severity and
transmission risk. Shedding rate is also a fundamental emergent
property of the model and therefore serves as the key outcome for
the remainder of this study.
MODEL PARAMETERS ARE OPTIMIZED FOR HIGH SHEDDING AT THE
POPULATION LEVEL
Each parameter set was assessed for its fit to a large empiri-
cal dataset of 14,685 swabs from 531 study participants (22).
The eight characteristics of shedding (see Materials and Meth-
ods) were measured in each simulation and compared to the
empirical data. Parameter sets with closets fit to the data (by
virtue of lowest least squares fitting test) also were closest to
the actual shedding rate (Figure 4). As simulated shedding rate
decreased below 18%, model fit generally decreased accordingly.
Most parameter sets resulted in shedding rates below that of the
population level value of 18%, suggesting that viral replication and
immune response parameters are relatively optimized to maximize
shedding (Figure 4).
HIGH TISSUE CD8+ T-CELL LEVELS DO NOT PREDICT LOWER SHEDDING
RATES
There was limited association between shedding rate and CD8+
T-cell density averaged over 10 years with a small positive correla-
tion between these two outcomes (Figure 5A). The reproductive
number in a single model region derives from the CD8+ T-cell
density with high levels of CD8+ lymphocytes driving the repro-
ductive number less than one. Under this condition, immediate
containment of infected cells is favored while much more extensive
local spread of HSV-2 to thousands of infected cells occurs at
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FIGURE 3 | Shedding rate is the most relevant measure of HSV-2
severity. (A) Typical model simulation demonstrating 365 days of shedding.
(B) Results from 200, 10-year model simulations, each with randomly
selected parameter values. Shedding rate correlates tightly with a
cumulative episode area under the curve indicating that shedding rate also
highly predicts quantitative levels of viral shedding.
higher reproductive numbers. The reproductive number,or poten-
tial for viral growth, averaged across the 300-model regions over
time, correlated inversely with shedding rate (Figure 5B) but was
significantly greater than one for all simulations with shedding
indicating high general potential for viral growth in all shedders
(Figure 5B).
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FIGURE 4 | Model parameters are optimized for high shedding. Results
from 200, 10-year model simulations, each with randomly selected
parameter values. Simulations with best fit to all features of shedding
episode features (rate, duration, early expansion and late decay kinetics,
peak viral production and, expansion and decay slopes) lead to lowest least
squares values (y -axis) and also most closely approximate the population
levels shedding rate of 18% (red line); only 40 of 200 parameter sets lead
to shedding rate >18%, implying that viral and immunologic parameters are
relatively well calibrated to allow maximal shedding. Black line is a Lowess
smoothed curve.
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FIGURE 5 | High shedding rate partially drives higher levels of CD8+
T-cell inflammation. Results from 200, 10-year model simulations, each
with randomly selected parameter values. (A) Shedding rate has a positive,
rather than a negative correlation with the average total amount of CD8+
T-cells in the genital tract over a 10-year period. (B) The average growth
potential (reproductive number) of all 300-model regions over 10 years in
high shedders, indicating that during the natural history of disease, high
shedding rate actually correlates with a slightly lower average growth
potential for virus across time and space.
HIGH SHEDDING RATE PREDICTS A MORE DYNAMIC CD8+ T-CELL
STATE
The total number of CD8+ T-cell births over 10-year correlated
positively with shedding rate, indicating that CD8+ births are
responsive to high level shedding (Figure 6A). The number of
CD8+ T-cell expansion events (defined as an increase of at least
10 CD8+ T-cells) also correlated with shedding rate (Figure 6B).
A higher number of shedding episodes increased the frequency of
CD8+ lymphocyte expansion (Figures 6C,D) leading to a more
dynamic inflammatory state.
SPATIAL HETEROGENEITY OF CD8+ T-CELL DENSITY AND
IMMUNOLOGIC READINESS IS PRESENT IN ALL INFECTED PERSONS
AND DOES NOT IMPACT SHEDDING RATE
The average standard deviation of CD8+ T–T-cell density
(Figure 7A) and the reproductive number (Figure 7B) across the
300 spatially discrete model regions did not vary according to shed-
ding rate, though the variability between regions was generally
high for all shedders suggesting substantial spatial heterogeneity
of immune readiness in persons with chronic HSV-2 infection.
Fewer than 50% of genital tract regions had reproductive number
<1 for all sets of parameters (Figure 7C), suggesting that most of
the genital tract can support high levels of HSV shedding at a sin-
gle point in time. This is consistent with genital biopsy studies that
reveal low CD8+ T-cell density in non-shedding regions (12, 13).
If the immunologic response to HSV-2 protected broad regions
of at risk tissue, then low CD8+ T-cell density regions in the
genital tract could be viewed as a limited ecologic “resource” for
the virus. To maximize shedding would require that HSV not
over utilize this resource by spreading rapidly to all susceptible
regions, thereby inducing high CD8+ T-cell levels across the gen-
ital tract. Theoretically, if episode initiation rate is too high due
to frequent release of HSV from neurons, then many spatially
separate episodes in the mucosa might overlap. Some shedding
might be wasted, as simultaneous shedding in different sites does
not increase the shedding rate. We measured number of aver-
age episode initiations per episode to assess this phenomenon.
Higher initiations per episode correlated tightly with shedding
rate in simulations, indicating that overlapping initiations, while
common, do not occur frequently enough to meaningfully lower
shedding rate (Figure 7D). Therefore, low CD8+T-cell regions do
not appear to be a limited resource for HSV-2 under any parame-
ter conditions, and multiple regions with low CD8+ T-cell density
allow breakthrough episodes in low and high shedders alike.
LIMITED EFFECT OF MUCOSAL CD8+ T-CELL FUNCTIONAL
PARAMETERS ON LONG-TERM SHEDDING RATE
Increased CD8+ T-cell expansion rate predicted a slight decrease
in shedding rate though this effect was limited (Figure 8A).
HSV-2 replication rate in keratinocytes, CD8+ T-cell regional
co-dependence (a measure of CD8+ T-cell diffusion between
regions), and CD8+ T-cell half-life had little predictive effect on
HSV-2 shedding rate in model simulations (Figures 8B–D). The
timing of recognition of infected cells by CD8+T-cells (parameter
r) had no impact on shedding rate (not shown).
LARGE EFFECT OF MUCOSAL NEURONAL RELEASE RATE OF HSV-2 ON
LONG-TERM SHEDDING RATE
In model simulations, shedding episodes are initiated when viruses
from neurons infect epithelial cells where replication and spread
is explosive, allowing HSV DNA to reach the skin surface. As a
result, increased shedding rate may theoretically be due to high
frequency of episodes, prolonged mean episode duration, or both.
Episode rate tightly correlated with shedding rate in simula-
tions (Figure 9A). On the other hand, episode duration had a
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FIGURE 6 | High shedding rate predicts a highly dynamic
immunologic state with more frequent CD8+T-cell turnover. (A)
Shedding rate predicts number of CD8+T-cell births over 10 years, and
strongly predicts (B) number of CD8+T-cell expansion events. (C) An
example of a high shedder (HSV DNA in red and CD8+T-cells in black) with
frequent CD8+T-cell reconstitution events. (D) An example of a low
shedder (HSV DNA in red and CD8+T-cells in black) with less common
CD8+T-cell reconstitution events.
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FIGURE 7 | Spatial heterogeneity in CD8+T-cell levels across the
genital tract does not explain variable shedding rates between
infected persons. The average (A) CD8+T-cell variability between
regions and (B) reproductive number variability between regions over
time, does not differ between low and high shedders. (C) Genital tract
regions with potential for high shedding (R<1) predominate among low
and high shedders. (D) High shedders have episodes with more region
initiations per detected episode than low shedders: therefore, initiation
of shedding in multiple regions per episode does not appear to decrease
shedding rate.
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FIGURE 8 | CD8+T-cell influenced parameters that are important
mediators of short-term viral control have only a limited impact on
long-term shedding rates. (A) CD8+T-cell expansion rate expansion rate
predicts slightly lower shedding rate. (B) HSV DNA replication rate has no
impact on shedding rate. (C) CD8+T-cell regional co-dependence, a model
parameter that dictates the range over which these cells provide protection,
has no impact on shedding rate. (D) Longer CD8+T-cell half-life weakly
predicts lower shedding rate.
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FIGURE 9 | Multiple episode initiations are the key driver of high
shedding rate. (A) High episode rate predicts high shedding rate to a
greater extent than (B) high mean episode duration (which is a summary
measure of mucosal control). Parameter values that allow more frequent
initiation of shedding episodes in the genital tract such as (C) high release
rate of HSV from neurons into genital skin and (D) low clearance rate of
free HSV particles from the genital tract, are most predictive of high
shedding rate.
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smaller predictive impact on shedding rate (Figure 9B). Episode
initiations in the model are predicted by the stochastic term
(β× S×V neu) with V neu initiated at a “drip rate” of ψ and
decay rate (V neu× c). Therefore, three parameters might influ-
ence episode rate viral infectivity (β), neuronal drip rate (ψ), and
viral clearance rate (c). Accordingly, both high neuronal release
rate of HSV (Figure 9C) and low viral clearance rate (Figure 9D)
predicted higher shedding rate. Viral infectivity also had a slight
positive predictive effect on shedding rate (R2= 0.09).
POSSIBLE THERAPEUTIC VACCINE INDUCED EFFECTS ON MUCOSAL
CONTROL OF HSV-2
Given the recently recognized importance of HSV specific mucosal
CD8+ effector memory T-cells for control of HSV-2, a current
therapeutic vaccine strategy is to increase the number of CD8+ T-
cells in the genital mucosa. Such a strategy might induce a uniform
increase in CD8+ T-cells, regardless of initial CD8+ T-cell lev-
els within specific micro-regions. Alternatively, increased CD8+
T-cell levels may depend on initial levels within each region if
the immunotherapy induces local replication of pre-existing cells.
Under this set of rules, any increase in local CD8+ lymphocyte
levels is relative to prior levels. Simulations demonstrate a dose
response for increase in number of tissue resident CD8+ T-cells,
and an added benefit for even distribution of recruited CD8+ T-
cells rather than focal accumulations at prior regions with high
levels (Figure 10).
DISCUSSION
I used a mathematical model to interrogate different compo-
nents of the immune response to a spatially dispersed frequently
relapsing infection and identified that increased genital tract T-
cell inflammation does not necessarily reflect better control of
infected cells. During the course of natural infection, numerous
dense focal islands of mucosal lymphocytes may indicate recent
episodes of breakthrough shedding rather than evidence of com-
prehensive protection against subsequent mucosal reactivation.
Even when total levels of HSV-2 specific CD8+ lymphocytes in
the genital tract are high, the model predicts, that regions with
low density predominate allowing breakthrough replication. This
result does not alter the fact that a high density of HSV specific
T-cells in mucosa might be a critical outcome for an immunother-
apy or a vaccine, but rather highlights the high degree of host/viral
co-dependence during unperturbed, chronic infection.
The model results also provide new hypotheses regarding shed-
ding heterogeneity among infected persons. Episode rate is a key
driver of shedding rate in simulations, a trend that is also observed
in empirical datasets (27). Factors, which promote more frequent
episode initiation, the most important of which may be rate of
viral release from ganglia, are important therapeutic targets. For
instance, ganglionic CD8+T-cells may exert control on HSV reac-
tivation via non-cytolytic means (31, 32). Surprisingly, parameters
of enhanced CD8+ T-cell functionality in mucosa that correlate
with better short-term containment of HSV may not mediate
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FIGURE 10 |Theoretical effect of an HSV-2 immunotherapy on yearly
shedding rates. We measured shedding rates for simulated patients with
25 parameter sets. Year 1 shedding rate represents 1-year shedding rate
pre-immunotherapy. Year 2 and 3 shedding rates are averaged over the
first and second year following immunotherapy, respectively. Each thin
colored line represents a simulation with an individual parameter set while
the thick black line represents median values for each year. Simulations
assume that immunotherapy leads to (A) 25% increase of total CD8+
T-cells applied within each individual region, (B) 50% increase of total
CD8+T-cells applied within each individual region, (C) 25% increase of
total CD8+T-cells applied evenly across all 300-modeled regions, and (D)
50% increase of total CD8+T-cells applied evenly across all 300-modeled
regions. An increase in total number of recruited CD8+T-cells (B,D), as
well as a more even recruitment of CD8+T-cells (C,D) leads to the largest
decline in shedding at year 2, though normal dynamics eventually return
leading to high shedding during year 3.
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enhanced long-term decreases in shedding rate. However, it is
unknown if the breadth and specificity of immunity in ganglia and
mucosa are mediated independently. Therefore, immune priming
in both neuronal and mucosal compartments may be an important
goal in development of immunotherapies (33).
Several caveats apply to these results. Mathematical models are
similar to animal models of infection in that they represent simpli-
fied abstractions of complex viral host interactions in humans. As
such, the model employed in this paper is a hypothesis generation
tool. My model, while mathematically complex, is immunologi-
cally simple, and negates most features of the highly coordinated
mucosal response including antigen presentation, CD4+ T-cell
help and innate responses. Moreover, I assume the possibility of
heterogeneity for all parameter values. In truth, certain parame-
ters are likely to be far more variable between infected persons
than others. However, there is a dearth of available information to
define these characteristics for human infections as most immuno-
logic measures are made in cross section rather than serially across
spatially complex microenvironments. As such, there is no way at
present to understand whether key parameters such as CD8+ T-
cell expansion rate or viral replication rate are stable or variable in
an uninfected person over time.
In addition, the predator prey structure of the model (with
CD8+ T-cells as predator and infected cells as prey) is critical to
its predictions regarding frequent CD8+ T-cell reconstitution in
genital tract, but is still based on theory. Indeed, predator prey
dynamics are not relevant for all types of immunity: the systemic,
humoral arm of the immune system appears to provide a durable
response over decades in the absence of antigenic re-stimulation
(34, 35). However, for HSV-2 there is sufficient proof to struc-
ture the model with the predator prey assumption: CD8+ T-cells
locally expand following a viral replication ulcer, and decay in
tissue slowly once virus is cleared (12, 13). The continued avail-
ability of prey (virus) is documented in studies from hundreds of
patients showing repeated episodic shedding over short time scales
of days to weeks. The spatial component of our model, which is
also based on detailed observations of gradients in viral and CD8+
T-cell quantity is tissue, has the potential to alter the predator prey
dynamics. Therefore, the dependence of inflammation quantity
(predator) on viral shedding (prey) is not a tautology of the model,
but rather a fundamental emergent property of simulations with
multiple parameter sets.
With these reservations in mind, the model’s results still serve an
important purpose. Like other human viruses, HSV-2 replicates in
a non-linear microenvironment with complex spatial constraints.
At minimum, these model results are a warning to immunologists
and vaccinologists to avoid certain traps that may arise from over
interpreting studies with cross-sectional design. First, results from
studies that use single, non-mechanistic measures of immunity
as correlates of less severe outcome, should not be used to infer
causality. Identifying true pathways of immune control in tissue
requires careful studies with serial sampling, as well as mathemat-
ical approaches to account for temporal and spatial non-linearity
in the system.
The limitations of human natural history studies must
be acknowledged: conditions cannot be controlled in obser-
vational cohorts and readout measures of infection severity
are complex. Animal models limit the complexity by focus-
ing precisely on pre-determined exposure variables and out-
come measures. Yet, infection conditions are artificial and
fail to capture the viral dynamics that represent co-evolution
between virus and host over millennia. Modeling is an ideal
method to analyze serial, observational human data. Moreover,
hypotheses raised in animal systems can be tested for their
applicability to human systems using competing mathematical
models.
This study highlights a new approach toward considering shed-
ding heterogeneity in HSV-2 infection that is widely applicable to
other human infections. Rather than focus on a specific molecu-
lar pathway, which correlates with severe disease in a minority of
infected people, we attempt to couch heterogeneity according to
definable parameters of CD8+ T-cell functionality and viral repli-
cation. The surprising result, that improvements in short-term
immune control may not correlate with improved long-term out-
comes, highlights the need for further studies in this discipline, as
well as for further collaborations between theorists and empirical
immunologists.
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